ClinicalTrials.gg
RecruitingNCT04657367PolReDUpdated Mar 26, 2025

Polish Registry of Diabetes (PolReD)

An observational study in Diabetes, Obesity and PreDiabetes, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Per ClinicalTrials.gov, last updated 2025-03-26.

Primary conditionPrediabetic StateRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prediabetic State
Why
  1. The study's listed conditions name Prediabetic State, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University of Bialystok · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Prediabetic State with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Prediabetic State · Poland.

Started
2020
with 1 other
Observational
2 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
4 of 11
Medical University of Bialystok

Among the 11 studies in Prediabetic State with a site in Poland, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 7th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

6 of the 11 studies in Prediabetic State with a site in Poland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prediabetic State with a site in Poland, or all of them as a file.
02

Study summary

The aim of this project is to create a registry of diabetic patients, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.

The study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.

Read the detailed description

The aim of this project is to create a registry of patients at risk of developing diabetes or already diagnosed with diabetes, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.

The study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.

As part of the project, each patient will participate in one visit at the research center. During the visit, each patient will undergo a detailed medical interview regarding the current health condition, the course of previously diagnosed diseases, family history, physical activity and diet. In addition, venous blood will be taken for each patient, from which the basic metabolic parameters will be determined (including glucose, lipid profile, HbA1c, AST, ALT, GGTP, electrolytes, blood count with smear, presence of antibodies against beta-cell antigens, TSH, ACTH) and omics analyzes will be performed (including genotyping and sequencing of DNA, transcriptomics, metabolomics, proteomics and lipidomics). Additionally, from each patient, saliva, urine, stool sample, and skin and nasal swabs to assess the microbiome will be collected. Each patient will also receive a detailed body composition analysis using bioimpedance and densitometry (DXA) and grip strength analysis. Non-diabetic patients will also undergo an oral glucose load test (OGTT).

In addition, patients who give additional consent will be able to participate in additional visits, including abdominal MR imaging with the assessment of liver steatosis, a biopsy of the vastus lateralis muscle, cardio-pulmonary exercise test, metabolic clamp (euglycemic - hyperinsulinemic) and glycemia assessment using the continuous glucose monitoring system ( CGM).

As part of the project, we plan for follow-up each participant with re-visits in the study centre every five years, covering exactly the same schedule of visits as the patient will make the first time.

03

Conditions studied

  • Diabetes
  • Obesity
  • PreDiabetes
  • Dysglycemia

Browse trials for

Keywords

  • diabetes registry
  • prediabetes registry
04

In context

Prediabetic State Reclassified

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 224 across 129 observational studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.

Compared within Prediabetic State, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The project participants will be patients with diabetes, patients at high risk of developing diabetes (prediabetes) and a control group of normoglycemic patients from Poland.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with diagnosed diabetes (according to the American Diabetes Association criteria) - diabetes group
  • patients with diagnosed prediabetes (IFG and/or IGT) - prediabetes group
  • patients with normoglycemia (NFG and NGT) - normoglycemia group

Exclusion criteria

Exclusion Criteria:

  • drug addiction
  • severe psychiatric disorders
  • patients with gestational diabetes mellitus
  • patients unable to give , legally incompetent or incapable to comply with the study terms and conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Diabetes

    Patients with diagnosed diabetes

    Other: Observational study - registry

  • Prediabetes

    Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance

    Other: Observational study - registry

  • Normoglycemia

    Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance

    Other: Observational study - registry

Interventions

  • OtherObservational study - registry

    Observational study - registry

07

What researchers measure

Primary outcomes

  1. HbA1c

    Haemoglobin A1c measured by the high-performance liquid chromatography (HPLC) method

    Time frame: every 5 years

  2. Fasting glucose

    Fasting glucose concentration measured in plasma using the colorimetric method

    Time frame: every 5 years

  3. 2-hour glucose

    Glucose concentration at 2-hour of the oral glucose tolerance test, measured in plasma using the colorimetric method - only in non-diabetic subjects

    Time frame: every 5 years

  4. Fasting insulin

    Fasting insulin concentration measured in plasma using the immunoradiometric assay (IRMA)

    Time frame: every 5 years

  5. Lean body mass

    Total lean body mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: every 5 years

  6. Fat mass

    Total body fat mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: every 5 years

  7. Visceral Adipose Tissue mass

    Visceral adipose tissue mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: every 5 years

  8. Weight

    Total body weight measured using standardized scale

    Time frame: every 5 years

  9. Homeostatic model assessment for insulin resistance (HOMA-IR)

    Homeostatic model assessment for insulin resistance

    Time frame: every 5 years

  10. Homeostatic model assessment of beta cell function (HOMA-beta)

    Homeostatic model assessment of beta cell function

    Time frame: every 5 years

  11. VO2max

    Maximal oxygen consumption measured during cardio-pulmonary exercise test

    Time frame: every 5 years

  12. Triglycerides (TG)

    Serum triglycerides concentration measured using colorimetric method

    Time frame: every 5 years

  13. High-density lipoprotein cholesterol (HDL)

    Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric meth

    Time frame: every 5 years

  14. Low-density lipoprotein cholesterol (LDL)

    Serum low-density lipoprotein cholesterol (LDL) concentration measured using colorimetric method

    Time frame: every 5 years

  15. Total cholesterol

    Serum total cholesterol concentration measured using colorimetric method

    Time frame: every 5 years

  16. Plasma metabolome

    plasma metabolites concentrations measured using untargeted metabolomics

    Time frame: every 5 years

  17. Skeletal muscle transcriptome

    skeletal muscle gene and smallRNA expressions measured using untargeted transcriptomics

    Time frame: every 5 years

  18. Skeletal muscle metabolome

    skeletal muscle metabolites concentrations measured using untargeted metabolomics

    Time frame: every 5 years

  19. Plasma microRNAs

    Expression of circulating smallRNA

    Time frame: every 5 years

08

Study locations

1 of 1 sites recruiting
  • Clinical Research Centre, Medical University of Bialystok
    Bialystok, Podlaskie 15-276, Poland
    Recruiting
    • Lukasz Szczerbinski, MD, PhD · Contactlukasz.szczerbinski@umb.edu.pl · +48 85 831 81 50
    • Adam Kretowski, Prof., MD, PhD · Principal investigator
    • Lukasz Szczerbinski, MD, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2030, 130 months after the start.

Of 48 observational studies under Prediabetic State, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 24. This study's planned 130 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Feb 3, 2020
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04657367
Lead sponsor
Medical University of Bialystok
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Feb 3, 2020
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 26, 2025

Study contacts

Lukasz Szczerbinski, MD, PhD
Contact
lukasz.szczerbinski@umb.edu.pl
+48858318150

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion